Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

NCT05642780 is registered in ClinicalTrials.gov with Klus Pharma Inc. as lead sponsor.

NCT NCT05642780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05642780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Lead sponsor
Klus Pharma Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 17, 2023
Completion date
December 31, 2027
Enrollment
240 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor